Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MANE

Veradermics Inc

Feb 13 • 04:00PM ET

43.46

-0.98 -2.21 %

Healthcare • Biotechnology • USA • NYSE

Index	-	P/E	-	EPS (ttm)	-	Insider Own	42.38%	Shs Outstand	35.08M	Perf Week	12.94%
Market Cap	1.52B	Forward P/E	-	EPS next Y	-	Insider Trans	23.66%	Shs Float	21.52M	Perf Month	-
Enterprise Value	1.57B	PEG	-	EPS next Q	-	Inst Own	20.33%	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	15.13%
Book/sh	-1.38	P/C	28.72	EPS next 5Y	-	ROE	-	52W High	45.78 -5.07%	Perf Year	-
Cash/sh	1.51	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	32.00 35.81%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.04% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	4.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	11.77	EPS Q/Q	-	SMA20	7.70%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	7.70%	Rel Volume	0.22	Prev Close	44.44
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	7.70%	Avg Volume	837.47K	Price	43.46
IPO	Feb 04, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	182,972	Change	-2.21%

Feb-12-26 08:55AM	NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell (PR Newswire)
Feb-09-26 07:30AM	Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss (Business Wire)
Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
Feb-05-26 04:05PM	Veradermics Announces Closing of Full Exercise of Underwriters Option to Purchase Additional Shares in Initial Public Offering (Business Wire)
Feb-04-26 04:12PM	No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. (Barrons.com)
01:07PM	Loading…
01:07PM	This week's first IPO is set for a warm Wall Street welcome (MarketWatch)
08:55AM	NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA (PR Newswire)
Feb-03-26 09:57PM	Veradermics Announces Pricing of Upsized Initial Public Offering (Business Wire)

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 04 '26	Buy	37.05	155,953	5,778,342	3,648,538	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 05 '26	Buy	37.99	96,200	3,655,079	489,932	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 06 '26	Buy	36.34	30,521	1,109,056	520,453	Feb 09 06:28 PM
Coric Vlad	Director	Feb 05 '26	Buy	17.00	117,646	1,999,982	319,398	Feb 05 07:04 PM
CHILDS JOHN W	Director	Feb 05 '26	Buy	17.00	294,117	4,999,989	2,202,006	Feb 05 07:04 PM
Longitude Capital Partners V,	10% Owner	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM
ENRIGHT PATRICK G	Director	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM

Open in Screener

BNTC

Benitec Biopharma Inc

Feb 13 • 04:00PM ET

10.38

-0.96 -8.47 %

Healthcare • Biotechnology • USA • NASD

BNTC Benitec Biopharma Inc daily Stock Chart

Peers: MRNA IONS ALNY CRSP ARWR NTLA SRPT EDIT SGMO QURE

| Held by: VTI IWM VXF IWO PINK VTWO IWC VTWG GSSC RSSL

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	2.74%	Shs Outstand	34.25M	Perf Week	-14.36%
Market Cap	355.52M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	178.15%	Shs Float	33.32M	Perf Month	-14.43%
Enterprise Value	167.61M	PEG	-	EPS next Q	-0.27	Inst Own	84.33%	Short Float	6.28%	Perf Quarter	-22.77%
Income	-38.96M	P/S	-	EPS this Y	-5.87%	Inst Trans	2.13%	Short Ratio	11.37	Perf Half Y	-18.01%
Sales	0.00M	P/B	1.90	EPS next Y	9.37%	ROA	-28.89%	Short Interest	2.09M	Perf YTD	-22.94%
Book/sh	5.47	P/C	1.88	EPS next 5Y	5.01%	ROE	-29.59%	52W High	17.15 -39.48%	Perf Year	7.01%
Cash/sh	5.52	P/FCF	-	EPS past 3/5Y	69.76% 62.31%	ROIC	-20.74%	52W Low	9.70 7.01%	Perf 3Y	126.31%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.27% 5.66%	Perf 5Y	-87.66%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	80.95%	Oper. Margin	-	ATR (14)	0.75	Perf 10Y	-98.80%
Dividend Ex-Date	-	Quick Ratio	67.69	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	33.21	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	67.69	EPS Q/Q	22.74%	SMA20	-13.67%	Beta	0.30	Target Price	25.20
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-15.69%	Rel Volume	0.93	Prev Close	11.34
Employees	19	LT Debt/Eq	0.00	Earnings	Feb 12 BMO	SMA200	-22.26%	Avg Volume	183.92K	Price	10.38
IPO	Jun 23, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.44% -	Trades		Volume	171,867	Change	-8.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-25	Initiated	TD Cowen	Buy
Dec-16-24	Initiated	H.C. Wainwright	Buy	$28
Dec-13-24	Initiated	Robert W. Baird	Outperform	$30
Oct-16-24	Initiated	Oppenheimer	Outperform	$35
Sep-12-24	Initiated	Guggenheim	Buy	$17
Jul-22-24	Initiated	Leerink Partners	Outperform	$13
Jun-13-24	Initiated	Piper Sandler	Overweight	$30
Oct-05-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Apr-20-20	Initiated	Ladenburg Thalmann	Buy	$14
Feb-26-16	Downgrade	Maxim Group	Buy → Hold
Dec-31-15	Reiterated	Maxim Group	Buy	$23 → $14
Sep-16-15	Reiterated	Maxim Group	Buy	$4 → $23

Show Previous Ratings

Feb-12-26 08:30AM	Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire)
Jan-11-26 08:00AM	Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response (GlobeNewswire)
Dec-24-25 09:55AM	Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect? (Zacks)
Dec-05-25 09:55AM	Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know (Zacks)
Dec-03-25 09:35AM	Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) (Zacks) +7.98%
06:16AM	Loading…
Nov-18-25 06:16AM	Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment (Insider Monkey)
Nov-14-25 05:00PM	Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-12-25 09:45AM	Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others (24/7 Wall St.)
Nov-06-25 12:19AM	Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering (GlobeNewswire) -23.95%
Nov-05-25 04:43PM	Benitec Biopharma Inc. Announces Proposed Public Offering (GlobeNewswire)
Nov-03-25 07:10AM	Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 (GlobeNewswire)
07:00AM	Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors (GlobeNewswire)
Nov-02-25 07:00PM	Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy (GlobeNewswire)
Sep-22-25 04:05PM	Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update (GlobeNewswire)
Jul-09-25 08:00AM	Benitec Biopharma Provides Operational Updates (GlobeNewswire) +9.67%
09:40AM	Loading…
Jun-20-25 09:40AM	Is Cintas (CTAS) Stock Outpacing Its Business Services Peers This Year? (Zacks)
09:40AM	Is Ardagh Metal Packaging (AMBP) Stock Outpacing Its Industrial Products Peers This Year? (Zacks)
09:40AM	Are Basic Materials Stocks Lagging Harmony Gold (HMY) This Year? (Zacks)
09:40AM	Is Root (ROOT) Stock Outpacing Its Finance Peers This Year? (Zacks)
09:40AM	Are Utilities Stocks Lagging CenterPoint Energy (CNP) This Year? (Zacks)
09:40AM	Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:40AM	Has Karooooo (KARO) Outpaced Other Computer and Technology Stocks This Year? (Zacks)
09:40AM	Are Consumer Staples Stocks Lagging Ahold (ADRNY) This Year? (Zacks)
09:40AM	Are Auto-Tires-Trucks Stocks Lagging Aisin Seiki (ASEKY) This Year? (Zacks)
Jun-16-25 08:50AM	Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jun-05-25 09:55AM	Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? (Zacks)
Jun-04-25 09:40AM	Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year? (Zacks)
May-29-25 08:50AM	Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why (Zacks)
May-20-25 09:55AM	Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet (Zacks)
May-19-25 09:40AM	Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year? (Zacks)
07:00AM	Loading…
May-14-25 07:00AM	Benitec Biopharma Releases Third Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 08:50AM	Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-02-25 09:40AM	Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
Apr-25-25 09:55AM	Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade (Zacks)
Apr-23-25 12:00PM	What Makes Benitec Biopharma (BNTC) a New Buy Stock (Zacks)
Apr-16-25 09:40AM	Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? (Zacks)
Apr-15-25 11:51PM	Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-25-25 08:00AM	Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering (GlobeNewswire)
Mar-19-25 07:00AM	Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Feb-26-25 07:00AM	Benitec Biopharma to Participate in Upcoming Conferences in March (GlobeNewswire)
Feb-20-25 09:55AM	Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know (Zacks)
Feb-14-25 08:10AM	Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update (GlobeNewswire) +15.98%
08:00AM	Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Jan-27-25 08:00AM	Benitec Biopharma to Participate in Upcoming Conferences in January and February (GlobeNewswire)
Jan-13-25 09:49AM	Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock (Zacks) -5.55%
Dec-17-24 06:25AM	Benitec Biopharma initiated with a Buy at H.C. Wainwright (TipRanks)
Dec-09-24 09:55AM	Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? (Zacks) +8.46%
08:50AM	Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-26-24 07:00AM	Benitec Biopharma to Participate in Upcoming Investor Conferences in December (GlobeNewswire)
Nov-14-24 04:30PM	Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-04-24 08:00AM	Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference (GlobeNewswire)
Oct-25-24 05:01PM	Janus Henderson Group PLC Expands Investment in Benitec Biopharma Inc (GuruFocus.com)
Oct-14-24 06:00AM	Benitec Biopharma Announces Updated Investor Webcast Information (GlobeNewswire) -6.45%
Oct-12-24 06:30AM	Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-30-24 09:03PM	Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc (GuruFocus.com) +19.42%
Sep-26-24 04:30PM	Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update (GlobeNewswire) +5.01%
Sep-18-24 08:00AM	Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-17-24 08:00AM	Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar (GlobeNewswire)
Jul-15-24 06:00AM	Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study (GlobeNewswire) +7.71%
Jul-01-24 07:00AM	Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors (GlobeNewswire)
May-13-24 02:53PM	BNTC Stock Earnings: Benitec Biopharma Misses EPS for Q3 2024 (InvestorPlace) -12.22%
08:15AM	Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
May-01-24 08:00AM	Benitec Biopharma to Participate in the Citizens JMP Life Science Conference (GlobeNewswire) -6.51%
Apr-18-24 07:30AM	Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study (GlobeNewswire) +42.08%
07:00AM	Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million (GlobeNewswire)
Apr-09-24 08:00AM	Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024 (GlobeNewswire)
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Feb-13-24 08:00AM	Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-30-23 07:00AM	Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (GlobeNewswire)
Nov-17-23 08:00AM	Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-13-23 08:00AM	Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Sep-21-23 08:00AM	Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Aug-21-23 09:02PM	Citadel Advisors LLC Acquires New Stake in Benitec Biopharma Inc (GuruFocus.com)
Aug-18-23 09:02PM	JANUS HENDERSON GROUP PLC Acquires New Stake in Benitec Biopharma Inc (GuruFocus.com)
Aug-11-23 01:00PM	Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering (GlobeNewswire)
Aug-08-23 10:30PM	Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering (GlobeNewswire) +65.80%
Jul-25-23 01:00PM	Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023 (GlobeNewswire)
Jun-26-23 08:00AM	Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (GlobeNewswire) +80.90%
May-15-23 08:00AM	Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire)
May-08-23 08:05AM	Benitec Biopharma to Present at the OPMD International Conference (GlobeNewswire)
08:00AM	Benitec Biopharma to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Feb-13-23 08:00AM	Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Jan-23-23 09:48AM	Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program (GlobeNewswire) +9.08%
Nov-10-22 08:00AM	Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire) +5.79%
Sep-16-22 08:42AM	Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering (GlobeNewswire) -15.43%
Sep-12-22 10:06PM	Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering (GlobeNewswire) -6.63% -28.34%
Sep-02-22 08:00AM	Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update (GlobeNewswire)
Jul-15-22 06:52AM	Having purchased US$827k worth of Benitec Biopharma Inc. (NASDAQ:BNTC) stock, the recent 11% pullback is not what insiders may have expected (Simply Wall St.) +7.00%
May-16-22 08:15AM	Benitec Biopharma Releases Q3 2022 Financial Results (GlobeNewswire) -8.79%
Feb-14-22 08:00AM	Benitec Biopharma Discloses Q2 2022 Financial Results (PR Newswire)
Jan-18-22 12:53PM	/C O R R E C T I O N from Source -- Norra Metals Corp./ (PR Newswire) -6.64%
Jan-17-22 09:30AM	Norra Metals Announces Private Placement Financing (PR Newswire)
Nov-27-21 06:54AM	We're Keeping An Eye On Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate (Simply Wall St.)
Nov-15-21 08:00AM	Benitec Biopharma Discloses Q1 2022 Financial Results (PR Newswire)
Sep-20-21 08:00AM	Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results (PR Newswire) -7.86%
Sep-13-21 03:58PM	Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference (PR Newswire)
Sep-08-21 08:10AM	Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022 (PR Newswire)
08:05AM	Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals (PR Newswire)

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 29 '25	Buy	13.44	77,387	1,040,081	9,700,195	Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 23 '25	Buy	12.85	50,000	642,500	9,620,075	Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 26 '25	Buy	13.10	16,836	220,552	9,634,395	Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 22 '25	Buy	12.08	19,542	236,067	9,577,475	Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 19 '25	Buy	11.48	16,384	188,088	9,560,825	Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Dec 18 '25	Buy	11.24	10,215	114,817	9,546,875	Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Nov 07 '25	Buy	13.50	1,481,481	19,999,994	9,538,175	Nov 10 09:51 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Mar 31 '25	Buy	12.83	16,497	211,736	8,807,805	Apr 02 04:37 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Mar 26 '25	Buy	13.00	900,000	11,700,000	8,793,245	Mar 28 04:51 PM
BUCHI J KEVIN	Director	Feb 27 '25	Option Exercise	3.86	51,813	199,998	103,910	Mar 03 02:20 PM

MANE

Veradermics Inc

BNTC

Benitec Biopharma Inc

Upgrade your FINVIZ experience